Proteon Therapeutics Announces Third Quarter 2015 Financial Results
November 12, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
-Enrollment in PATENCY-1 Completed Ahead of Schedule-
-Data from PATENCY-1 Expected in December 2016-
-Proteon to Hold Research and Development Day in New York on November 20-
WALTHAM, Mass.,...
Proteon Therapeutics to Host Research and Development Day on November 20, 2015
November 09, 2015 11:58 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Completes Enrollment in PATENCY-1, First Phase 3 Clinical Study of Investigational Vonapanitase
November 02, 2015 16:15 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics to Present at the BIO-Europe 2015 Conference November 3
October 28, 2015 17:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Appoints Tony Kingsley to Its Board of Directors
October 19, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015
October 12, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics to Present at Two Upcoming Investor Conferences
September 02, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Appoints Jennifer Panagoulias as Vice President of Regulatory Affairs
September 01, 2015 07:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Announces Second Quarter 2015 Financial Results
August 13, 2015 17:15 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease
August 13, 2015 16:45 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...